Biosimilar User Fee Act (BsUFA) | Association for Accessible Medicines
AAM All Access Podcast - Dan Leonard speaks with Mary Beth Powers, President and CEO of CMMB.

Biosimilar User Fee Act (BsUFA)

GDUFA and BsUFA User Fees

What are GDUFA and BsUFA user fees? Watch this this video to learn more about how the Generic Drug User Fee Amendments (GDUFA) and Biosimilar User Fee Act (BsUFA) help to get more generic and biosimilar medicines to patients more quickly. Over ten years, the generic and biosimilar industry has provided the FDA over $4 billion for review and approval of lower-cost treatments for America’s patients. The result is more than $2 trillion in savings to patients and a dramatic increase in patient access to life-saving treatments.

 

AAM Statement on FDA User Fee Reauthorization

WASHINGTON D.C. (February 2, 2022) – AAM strongly supports congressional reauthorization of GDUFA and BsUFA as negotiated and without changes. Timely approval of the FDA user fee agreements will ensure that patients continue to benefit from new, more affordable generic and biosimilar medicines. GDUFA III and BsUFA III are the culmination of months of negotiations, have been subject to public review and comment, and represent a careful balance between stakeholders.

Subscribe to Biosimilar User Fee Act (BsUFA)

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.